323 related articles for article (PubMed ID: 38111057)
1. Targeting RACK1 to alleviate TDP-43 and FUS proteinopathy-mediated suppression of protein translation and neurodegeneration.
Zhao B; Cowan CM; Coutts JA; Christy DD; Saraph A; Hsueh SCC; Plotkin SS; Mackenzie IR; Kaplan JM; Cashman NR
Acta Neuropathol Commun; 2023 Dec; 11(1):200. PubMed ID: 38111057
[TBL] [Abstract][Full Text] [Related]
2. Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice.
Igaz LM; Kwong LK; Lee EB; Chen-Plotkin A; Swanson E; Unger T; Malunda J; Xu Y; Winton MJ; Trojanowski JQ; Lee VM
J Clin Invest; 2011 Feb; 121(2):726-38. PubMed ID: 21206091
[TBL] [Abstract][Full Text] [Related]
3. Increased cytoplasmic TDP-43 reduces global protein synthesis by interacting with RACK1 on polyribosomes.
Russo A; Scardigli R; La Regina F; Murray ME; Romano N; Dickson DW; Wolozin B; Cattaneo A; Ceci M
Hum Mol Genet; 2017 Apr; 26(8):1407-1418. PubMed ID: 28158562
[TBL] [Abstract][Full Text] [Related]
4. Conjoint pathologic cascades mediated by ALS/FTLD-U linked RNA-binding proteins TDP-43 and FUS.
Ito D; Suzuki N
Neurology; 2011 Oct; 77(17):1636-43. PubMed ID: 21956718
[TBL] [Abstract][Full Text] [Related]
5. Altered mRNP granule dynamics in FTLD pathogenesis.
Bowden HA; Dormann D
J Neurochem; 2016 Aug; 138 Suppl 1():112-33. PubMed ID: 26938019
[TBL] [Abstract][Full Text] [Related]
6. Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA-binding protein of 43 kDa (TDP-43).
Bentmann E; Neumann M; Tahirovic S; Rodde R; Dormann D; Haass C
J Biol Chem; 2012 Jun; 287(27):23079-94. PubMed ID: 22563080
[TBL] [Abstract][Full Text] [Related]
7. The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients.
Collins M; Riascos D; Kovalik T; An J; Krupa K; Krupa K; Hood BL; Conrads TP; Renton AE; Traynor BJ; Bowser R
Acta Neuropathol; 2012 Nov; 124(5):717-32. PubMed ID: 22993125
[TBL] [Abstract][Full Text] [Related]
8. Physiological functions and pathobiology of TDP-43 and FUS/TLS proteins.
Ratti A; Buratti E
J Neurochem; 2016 Aug; 138 Suppl 1():95-111. PubMed ID: 27015757
[TBL] [Abstract][Full Text] [Related]
9. How do the RNA-binding proteins TDP-43 and FUS relate to amyotrophic lateral sclerosis and frontotemporal degeneration, and to each other?
Baloh RH
Curr Opin Neurol; 2012 Dec; 25(6):701-7. PubMed ID: 23041957
[TBL] [Abstract][Full Text] [Related]
10. Mislocated FUS is sufficient for gain-of-toxic-function amyotrophic lateral sclerosis phenotypes in mice.
Shiihashi G; Ito D; Yagi T; Nihei Y; Ebine T; Suzuki N
Brain; 2016 Sep; 139(Pt 9):2380-94. PubMed ID: 27368346
[TBL] [Abstract][Full Text] [Related]
11. Stress granules in neurodegeneration--lessons learnt from TAR DNA binding protein of 43 kDa and fused in sarcoma.
Bentmann E; Haass C; Dormann D
FEBS J; 2013 Sep; 280(18):4348-70. PubMed ID: 23587065
[TBL] [Abstract][Full Text] [Related]
12. Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS.
Sun Z; Diaz Z; Fang X; Hart MP; Chesi A; Shorter J; Gitler AD
PLoS Biol; 2011 Apr; 9(4):e1000614. PubMed ID: 21541367
[TBL] [Abstract][Full Text] [Related]
13. Human TDP-43 and FUS selectively affect motor neuron maturation and survival in a murine cell model of ALS by non-cell-autonomous mechanisms.
Wächter N; Storch A; Hermann A
Amyotroph Lateral Scler Frontotemporal Degener; 2015; 16(7-8):431-41. PubMed ID: 26174443
[TBL] [Abstract][Full Text] [Related]
14. Inclusions in frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP) and amyotrophic lateral sclerosis (ALS), but not FTLD with FUS proteinopathy (FTLD-FUS), have properties of amyloid.
Bigio EH; Wu JY; Deng HX; Bit-Ivan EN; Mao Q; Ganti R; Peterson M; Siddique N; Geula C; Siddique T; Mesulam M
Acta Neuropathol; 2013 Mar; 125(3):463-5. PubMed ID: 23378033
[No Abstract] [Full Text] [Related]
15. Atypical FTLD-FUS associated with ALS-TDP: a case report.
Kobayashi Z; Arai T; Yokota O; Tsuchiya K; Hosokawa M; Oshima K; Niizato K; Akiyama H; Mizusawa H
Neuropathology; 2013 Feb; 33(1):83-6. PubMed ID: 22640227
[TBL] [Abstract][Full Text] [Related]
16. FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations.
Neumann M; Bentmann E; Dormann D; Jawaid A; DeJesus-Hernandez M; Ansorge O; Roeber S; Kretzschmar HA; Munoz DG; Kusaka H; Yokota O; Ang LC; Bilbao J; Rademakers R; Haass C; Mackenzie IR
Brain; 2011 Sep; 134(Pt 9):2595-609. PubMed ID: 21856723
[TBL] [Abstract][Full Text] [Related]
17. Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43.
Walker AK; Spiller KJ; Ge G; Zheng A; Xu Y; Zhou M; Tripathy K; Kwong LK; Trojanowski JQ; Lee VM
Acta Neuropathol; 2015 Nov; 130(5):643-60. PubMed ID: 26197969
[TBL] [Abstract][Full Text] [Related]
18. Motor neuron TDP-43 proteinopathy in progressive supranuclear palsy and corticobasal degeneration.
Riku Y; Iwasaki Y; Ishigaki S; Akagi A; Hasegawa M; Nishioka K; Li Y; Riku M; Ikeuchi T; Fujioka Y; Miyahara H; Sone J; Hattori N; Yoshida M; Katsuno M; Sobue G
Brain; 2022 Aug; 145(8):2769-2784. PubMed ID: 35274674
[TBL] [Abstract][Full Text] [Related]
19. Fused in sarcoma (FUS) protein lacking nuclear localization signal (NLS) and major RNA binding motifs triggers proteinopathy and severe motor phenotype in transgenic mice.
Shelkovnikova TA; Peters OM; Deykin AV; Connor-Robson N; Robinson H; Ustyugov AA; Bachurin SO; Ermolkevich TG; Goldman IL; Sadchikova ER; Kovrazhkina EA; Skvortsova VI; Ling SC; Da Cruz S; Parone PA; Buchman VL; Ninkina NN
J Biol Chem; 2013 Aug; 288(35):25266-25274. PubMed ID: 23867462
[TBL] [Abstract][Full Text] [Related]
20. TDP-43 and FUS/TLS: cellular functions and implications for neurodegeneration.
Fiesel FC; Kahle PJ
FEBS J; 2011 Oct; 278(19):3550-68. PubMed ID: 21777389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
